BUCHLER, Tomas, Igor KISS, Jana HORNOVA, Ondrej FIALA, Marketa WIESNEROVA, Michal SVOBODA, Jiri SILAR, Katerina KOPECKOVA, Alexandr POPRACH, Jindrich FINEK, Lubos PETRUZELKA a Bohuslav MELICHAR. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Targeted Oncology. Dordrecht: Springer, roč. 15, č. 2, s. 193-201. ISSN 1776-2596. doi:10.1007/s11523-020-00705-1. 2020.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice
Autoři BUCHLER, Tomas (203 Česká republika, garant), Igor KISS (203 Česká republika, domácí), Jana HORNOVA (203 Česká republika), Ondrej FIALA (203 Česká republika), Marketa WIESNEROVA (203 Česká republika), Michal SVOBODA (203 Česká republika), Jiri SILAR (203 Česká republika), Katerina KOPECKOVA (203 Česká republika), Alexandr POPRACH (203 Česká republika, domácí), Jindrich FINEK (203 Česká republika), Lubos PETRUZELKA (203 Česká republika) a Bohuslav MELICHAR (203 Česká republika).
Vydání Targeted Oncology, Dordrecht, Springer, 2020, 1776-2596.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Nizozemské království
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.493
Kód RIV RIV/00216224:14110/20:00116027
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1007/s11523-020-00705-1
UT WoS 000513061300001
Klíčová slova anglicky SIAN PATIENTS; SAFETY; FLUOROURACIL; COMBINATION; LEUCOVORIN; IRINOTECAN; EFFICACY
Štítky 14110811, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 17. 7. 2020 10:07.
Anotace
Background Bevacizumab and aflibercept are currently the mainstay of antiangiogenic therapy for metastatic colorectal carcinoma (mCRC). They are often used in sequence with first- and second-line chemotherapy, especially in patients with RAS-mutated tumours. Objective The aim of the present study was to investigate the outcomes of patients with mCRC treated with the bevacizumab-aflibercept sequence in real-world clinical practice. Patients and Methods Data from a national clinical registry of targeted therapies for mCRC were analysed retrospectively. Overall, there were 366 patients with valid data who received first-line treatment with bevacizumab and chemotherapy followed by aflibercept with chemotherapy. The majority of the patients (n = 296, 80.8%) had RAS mutated tumours. Results Median cumulative progression-free survival (PFS) from the start of the bevacizumab-containing regimen to progression on aflibercept was 18.2 months (95% CI 16.8-19.5). Median PFS for bevacizumab and aflibercept was 10.6 months (95% CI 9.5-11.7) and 5.6 months (95% CI 5.1-6.1), respectively. Longer PFS on aflibercept was associated with metachronous metastatic disease and longer PFS on bevacizumab. Median overall survival (OS) from the start of first-line bevacizumab was 32.0 months (95% CI 26.6-37.5). The presence of metastatic disease at diagnosis was associated with worse OS. Conclusions Patients treated with aflibercept in real-world clinical practice achieved similar survival outcomes as those treated within randomised trials. Cumulative survival data provide a benchmark for future studies and enable indirect comparisons with other treatment sequences used in mCRC.
VytisknoutZobrazeno: 28. 3. 2024 14:41